History of Semax: From Soviet Lab to Nootropic
Semax Neuropeptide
40+ years of research
Semax has been studied since the early 1980s at the Russian Academy of Sciences. It remains a prescription drug in Russia while attracting growing Western nootropic interest.
Dolotov et al., J Neurosci Res, 2006
Dolotov et al., J Neurosci Res, 2006
View as imageIn the early 1980s, researchers at the Institute of Molecular Genetics of the Soviet Academy of Sciences began modifying a fragment of adrenocorticotropic hormone (ACTH) to create a peptide that could enhance brain function without affecting the adrenal glands. The result was Semax, a seven-amino-acid synthetic peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Over the next four decades, Semax became one of the most extensively studied neuropeptides in Russian pharmacology, earning a place on the Russian List of Vital and Essential Drugs in 2011. It has never been evaluated or approved by the FDA or EMA. Despite this, it has become one of the most popular research peptides in the Western nootropic community. For a broad overview of how Semax upregulates BDNF, the primary mechanism behind its effects, see the cluster pillar.
Key Takeaways
- Semax is a synthetic analog of ACTH(4-10) developed at the Institute of Molecular Genetics of the Soviet/Russian Academy of Sciences beginning in 1982
- It increases BDNF protein levels in the rat hippocampus, frontal cortex, and basal forebrain through specific receptor binding[1][2]
- In animal models of ischemic stroke, Semax provided neuroprotection and reduced amnesia when administered within the acute phase[3]
- Semax has been approved as a prescription drug in Russia since 2011 for stroke recovery, cognitive impairment, and optic nerve disease
- No randomized, placebo-controlled clinical trials have been published in English-language journals
- A 2025 study found Semax and its derivative improved spatial memory and reduced amyloid-beta pathology in an Alzheimer's disease mouse model[7]
The ACTH Fragment That Lost Its Hormonal Activity
The story of Semax begins with a simple observation about ACTH, the 39-amino-acid pituitary hormone best known for stimulating cortisol release from the adrenal glands. In the 1960s and 1970s, researchers discovered that fragments of ACTH retained neurotrophic and cognitive effects in animal models even when they were too short to activate adrenal receptors. The fragment ACTH(4-10), just seven amino acids from the middle of the hormone, improved learning and memory in rats without triggering any cortisol release.
The problem was stability. ACTH(4-10) was rapidly degraded by peptidases in the blood and brain, giving it a half-life measured in minutes. A team led by Academician I.P. Ashmarin at the Institute of Molecular Genetics set out to solve this. Beginning in 1982, they systematically modified the C-terminal end of ACTH(4-10), eventually adding a Pro-Gly-Pro (PGP) tripeptide tail that protected the molecule from enzymatic degradation while preserving its neurotrophic activity.
The final compound was named Semax: Met-Glu-His-Phe-Pro-Gly-Pro. It retained the cognitive-enhancing properties of the ACTH fragment but was stable enough for nasal administration and had a functional half-life that made clinical use feasible.
The BDNF Connection: Mechanism Takes Shape
Through the 1990s and 2000s, Semax research focused on understanding how a seven-amino-acid peptide could produce such broad neurological effects. The key finding came from the laboratory of Dolotov and colleagues.
In 2003, Dolotov demonstrated that Semax stimulated BDNF (brain-derived neurotrophic factor) expression in multiple areas of the rat brain, including the hippocampus, frontal cortex, and brainstem.[1] BDNF is the brain's primary growth factor for neurons: it promotes neuronal survival, strengthens synaptic connections, and supports neuroplasticity. Low BDNF levels are associated with depression, cognitive decline, and neurodegeneration.
In 2006, Dolotov's group showed that Semax binds specifically to receptors in the rat basal forebrain and increases BDNF protein levels in a dose-dependent manner.[2] This was not a nonspecific stress response; Semax appeared to directly upregulate BDNF production through a targeted receptor interaction. The exact receptor has not been definitively identified, but it is distinct from the melanocortin receptors that mediate ACTH's hormonal effects.
This BDNF mechanism provides a plausible explanation for the range of effects observed in animal studies: neuroprotection after stroke, improved memory consolidation, enhanced learning in cognitive tasks, and resistance to stress-induced behavioral changes. BDNF upregulation would be expected to produce all of these effects. For a complete analysis of the BDNF mechanism, see the dedicated pillar article.
Neuroprotection Research: Stroke and Ischemia
Semax's neuroprotective properties in stroke models represent the most clinically developed area of research. Romanova and colleagues demonstrated in 2006 that Semax reduced the volume of ischemic damage and prevented amnesia in rats with experimentally induced cerebral cortex infarction.[3] The neuroprotective effect was observed when Semax was administered during the acute phase of ischemia.
Medvedeva and colleagues extended this work in 2017, showing that Semax regulated the expression of immune response genes during ischemic brain injury.[4] Specifically, Semax modulated inflammatory gene expression in the ischemic penumbra (the at-risk tissue surrounding the core infarct), suggesting that its neuroprotective mechanism involves immune modulation as well as direct neurotrophic support. This dual mechanism, BDNF upregulation plus immune modulation, may explain why Semax showed broader neuroprotection than agents targeting only one pathway.
These stroke studies formed the primary basis for Semax's regulatory approval in Russia. For a deeper review of Semax for stroke recovery, see the dedicated analysis.
Russian Regulatory Approval and Clinical Use
Semax was added to the Russian List of Vital and Essential Drugs on December 7, 2011. In Russia, it is prescribed as a 0.1% and 1% intranasal solution for:
- Acute ischemic stroke (0.1% solution during the acute phase and early rehabilitation)
- Cognitive impairment associated with cerebrovascular disease
- Optic nerve atrophy (1% solution, applied intranasally)
- Cognitive enhancement in healthy individuals under stress (0.1% solution)
The regulatory basis for approval included Russian clinical studies on stroke patients, though these studies have not been published in English-language peer-reviewed journals with the level of detail expected by Western regulatory agencies. The absence of randomized, double-blind, placebo-controlled trial data in international journals means that Semax's clinical evidence base is difficult to evaluate by FDA or EMA standards. This is a recurring challenge with Russian peptide drugs: the clinical data exists in Russian-language databases but has not been subjected to the trial design standards required for international regulatory approval.
Semax is administered intranasally, which allows the peptide to reach the brain through the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. For a detailed look at how Semax reaches the brain through nasal delivery, see the dedicated article.
Expanding the Research: Beyond Stroke
Over the past decade, Semax research has branched into several new areas.
Stress and Depression
Inozemtseva and colleagues published a 2024 study comparing the antidepressant-like and antistress effects of Semax and Melanotan II (another ACTH-related peptide) in rats subjected to chronic unpredictable stress.[5] Semax attenuated stress-induced behavioral changes, including anxiety-like behavior and anhedonia. The effect was comparable to that of the antidepressant imipramine in some behavioral measures. These are animal results only, but they expand the potential application profile beyond acute neuroprotection.
ADHD and Neurodevelopment
A 2007 paper by Tsai proposed Semax as a potential agent for attention-deficit hyperactivity disorder (ADHD) and Rett syndrome, based on its BDNF-modulating and dopaminergic properties.[6] The rationale was pharmacological: both conditions involve dopaminergic dysfunction and reduced neurotrophic support, and Semax activates both systems. This remains a theoretical proposal. No clinical trials for ADHD or Rett syndrome have been conducted.
Neurodevelopmental Protection
Glazova and colleagues showed in 2021 that Semax attenuated behavioral and neurochemical changes in rats that had been exposed to the SSRI fluvoxamine during early life.[5] Early-life SSRI exposure can disrupt serotonergic development and produce lasting behavioral changes; Semax appeared to partially reverse these effects. The finding suggests a potential role in neurodevelopmental protection, though this has not been studied in humans.
Alzheimer's Disease
The most recent direction is Alzheimer's research. Radchenko and colleagues published a 2025 study testing Semax and its derivative in a mouse model of Alzheimer's disease.[7] The peptides improved spatial memory performance, reduced amyloid-beta accumulation, and decreased neuroinflammatory markers. This is early-stage preclinical work, but it connects Semax to one of the largest unmet needs in neurology.
The Western Nootropic Market
Semax is not approved for any indication outside of Russia and a few other former Soviet states. It has no regulatory status in the United States, EU, UK, Australia, or Canada. It is not scheduled as a controlled substance in most jurisdictions.
Despite this, Semax has become widely available through online peptide vendors, marketed as a nootropic (cognitive enhancer). Users typically administer it as a nasal spray and report subjective improvements in focus, mental clarity, and motivation. These reports are anecdotal and cannot substitute for controlled trial data.
The Western interest in Semax parallels broader trends in the nootropic peptide space. For an overview of nootropic peptides as cognitive enhancers, see the general review. Semax is frequently discussed alongside Selank, another Russian peptide derived from a different immunoglobulin fragment that targets anxiety rather than cognition. Both come from the same Soviet-era research tradition that produced Khavinson's peptide bioregulators, reflecting a Russian pharmacological approach to peptide drug development that has remained largely separate from Western pharmaceutical development pipelines.
What's Missing from the Evidence
The Semax literature has several notable gaps:
No international clinical trials. The Russian clinical data that supported regulatory approval has not been replicated or independently verified in trials meeting ICH-GCP (International Council for Harmonisation Good Clinical Practice) standards. Without these, the human efficacy data is impossible to evaluate with confidence.
Receptor identity unknown. Despite over 40 years of research, the specific receptor through which Semax exerts its BDNF-modulating effects has not been definitively identified. The melanocortin receptors are not responsible; an unknown target remains.
Single-country research base. The majority of Semax research comes from Russian institutions, particularly the Institute of Molecular Genetics. While this does not invalidate the findings, the lack of independent international replication is a limitation that parallels concerns in other peptide fields.
No pharmacokinetic data in English. Basic questions about Semax's absorption, distribution, metabolism, and elimination in humans have not been published in the international literature. What happens to the peptide after intranasal administration, how much reaches the brain, and how long it remains active are not fully characterized in accessible publications.
For a comprehensive look at what Semax does for memory and cognitive performance, see the dedicated evidence review. The broader question of what the Russian nootropic peptide landscape looks like contextualizes Semax within its pharmacological tradition.
The Bottom Line
Semax is a synthetic ACTH(4-10) analog developed in the Soviet Union in the 1980s, with over 40 years of research primarily from Russian institutions. Its primary mechanism involves upregulation of BDNF in multiple brain regions, and its most developed clinical application is neuroprotection after ischemic stroke. It is a prescription drug in Russia but has no regulatory status elsewhere. The absence of international clinical trials, unknown receptor identity, and limited pharmacokinetic data in English represent significant evidence gaps despite the breadth of preclinical research.